(g) whether it is a fact that norms allowed are much higher than the actuals ; and

(h) if so, what steps have been taken to rectify the anomaly ?

THE MINISTER OF PETROLEUM AND CHEMICALS (SHRI M. S. GURUPADASWAMY) : (a) to (e) After the promulgation of the Drugs (Prices Control) Order, 1987, a Committee was constituted in September, 1987, under the Chairmanship of the then Director (Pharmaceutical Industry) for revision of conversion and packing norms. Based on the recommendations contained in the report of the norms committee, the revised norms for conversion cost, packing charges and process loss of material were announced in February, 1989 vide order S.O. No. 130(E) superceeding the earlier norms announced under DPCO, 1979 vide order S.O. 259(E) dated 3-5-1979.

(c) and (d) The material cost depends on price of bulk drug and excipient whereas the conversion cost and packing charges are unrelated to material cost and are more or less uniform for a particular type of formulation e.g. tablets, capsules. In case the price of the bulk drug is lower such situation may occur.

(f) It is Rs. 0·15 for both.

(g) and (h) No; Sir. While fixing the prices of formulations either the ceilings or the actuals, wherever is lower, are taken into account.

Multinational drug companies marketing products manufactured by Small Scale Units

1344. SMT. SATYA BAHIN : Will the Minister of PETROLEUM AND CHEMICALS be pleased to refer to the answer to Unstarred Question 1348 given in the Rajya Sabha on the 21st May, 1990 and state :

(a) whether it is a fact that most of the major multinational companies are marketing a number of their products manufactured by small scale units without price approval ;

(b) if so, what are the names of 18 such major multinational drug companies, the names of the products of each and the present MRP of each ;

(c) whether it is also a fact that annual sales turn-over of certain small scale drug companies are much higher than the organised sector units ;

(d) what is the annual sales turn-over of five major small scale sector units ; and

(e) what are the details of other recommendations where his Ministry have taken independent decision ?

THE MINISTER OF PETROLEUM AND CHEMICALS (SHRI M. S. GURUPADASWAMY) : (a) and (b) The requisite information, to the extent available, is given in the Annexed Statement. (*See* below).

(c) and (d) Sales turnover of individual units are not monitored.

(e) The requisite information has already been furnished in reply to Rajya Sabha Unstarred Question No. 868 answered on 13-8-1990.

Statement

S. No.	Name of the companies	Name of formulation	MRP as per MIMS, July 1990	Pack size
1	M/s. Carews/Roussel	Combiflam tablets	Rs. 8.25	10's
2	M/s. Denis Pharmacy/ M/s. May & Baker	Flagyl I.V. Injection	Rs. 13.34	100 m.l. bottle
3	M/s. Biodeal/ M/s. May & Baker	Flagyl F tablets	Rs. 4.55	10's
4	Do.	Flagyl F suspension	Rs. 7.95	60 m.l. bottle

N.B.:—As per available information these formulations were being marketed without price approval at one point of time.

Decontrol of Psychotherapeutic Drugs

1345. **SHRIMATI KAILASHPATI :**
SHRIMATI PRATIBHA SINGH :

Will the Minister of PETROLEUM AND CHEMICALS be pleased to refer to the answer to Unstarred Question No. 1347 given in the Rajya Sabha on the 21st May, 1990 and state:

(a) whether it is a fact that decontrol recommended by Health Ministry was subject to Psychotherapeutic drugs satisfying the criteria of Kelkar Committee;

(b) when was the matter referred to Health Ministry and when their opinion received and when was it communicated to Kelkar Committee;

(c) whether his Ministry sought the opinion from Health Ministry on any other drug also;

(d) if so, what are the details of such drugs and when was the opinion sought, and what were the details of their opinion on each;

(e) whether it is a fact that his Ministry did not fix the prices of formulations from 26th August, 1987 till the removal of these drugs from price control; and

(f) if so, what are the reasons therefor?

THE MINISTER OF PETROLEUM AND CHEMICALS (SHRI M. S. GURUPADASWAMY): (a) and (b) The basis on which Psychotherapeutic drugs have been excluded from price control have been explained in detail by the Kelkar Committee in its Supplementary Report, copies of which are available in the Parliament Library.

(c) and (d) Yes, Sir. The opinion of Health Ministry was also obtained on Paracetamol. Details of its exclusion from price control are discussed in the Supplementary Report of the Kelkar Committee.

(e) and (f) The requisite information is being collected and will be laid on the Table of the House.